

Stuart J Connolly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11657861/publications.pdf>

Version: 2024-02-01

398
papers

70,255
citations

1040

113
h-index

621

258
g-index

401
all docs

401
docs citations

401
times ranked

30739
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
2	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	13.9	2,207
3	Subclinical Atrial Fibrillation and the Risk of Stroke. <i>New England Journal of Medicine</i> , 2012, 366, 120-129.	13.9	1,751
4	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
5	Canadian Implantable Defibrillator Study (CIDS). <i>Circulation</i> , 2000, 101, 1297-1302.	1.6	1,455
6	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2667-2677.	13.9	1,421
7	Prophylactic Use of an Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 2481-2488.	13.9	1,358
8	Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 2066-2078.	13.9	1,273
9	Embolic strokes of undetermined source: the case for a new clinical construct. <i>Lancet Neurology</i> , The, 2014, 13, 429-438.	4.9	1,268
10	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	13.9	1,201
11	Canadian atrial fibrillation anticoagulation (CAFA) study. <i>Journal of the American College of Cardiology</i> , 1991, 18, 349-355.	1.2	1,128
12	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
13	Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 668-678.	13.9	1,029
14	Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. <i>Lancet</i> , The, 1997, 349, 675-682.	6.3	915
15	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet</i> , The, 2010, 376, 975-983.	6.3	913
16	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015, 373, 2413-2424.	13.9	907
17	Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. <i>American Journal of Cardiology</i> , 1983, 52, 490-494.	0.7	838
18	Randomized Trial of Benznidazole for Chronic Chagas's™ Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 1295-1306.	13.9	807

#	ARTICLE	IF	CITATIONS
19	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
20	Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1832-1839.	1.2	774
21	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	1.2	733
22	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	13.9	730
23	Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes. <i>New England Journal of Medicine</i> , 2000, 342, 1385-1391.	13.9	704
24	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
25	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
26	Comparison of β -Blockers, Amiodarone Plus β -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators<SUBTITLE>The OPTIC Study: A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 165.	3.8	672
27	Newly Identified Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2010, 363, 1875-1876.	13.9	652
28	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
29	Dronedaron for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. <i>New England Journal of Medicine</i> , 2007, 357, 987-999.	13.9	597
30	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
31	Dronedaron in High-Risk Permanent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2268-2276.	13.9	547
32	Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 692.	3.8	533
33	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	13.9	497
34	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
35	Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2224.	3.8	453
36	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	1.6	447

#	ARTICLE	IF	CITATIONS
37	Prevention of Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 606-618.	1.6	446
38	Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 131-136.	1.6	446
39	Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery. <i>Circulation</i> , 2002, 106, 75-80.	1.6	442
40	Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. <i>American Heart Journal</i> , 2005, 150, 288-293.	1.2	436
41	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
42	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 205-218.	6.3	426
43	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2156-2161.	1.2	422
44	Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 867-872.	1.0	408
45	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	4.9	399
46	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	6.3	389
47	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517.	1.0	385
48	Historical criteria that distinguish syncope from seizures. <i>Journal of the American College of Cardiology</i> , 2002, 40, 142-148.	1.2	358
49	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	1.6	348
50	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346
51	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
52	New-Onset Atrial Fibrillation. <i>Circulation</i> , 2001, 103, 2365-2370.	1.6	344
53	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324
54	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. <i>New England Journal of Medicine</i> , 2021, 384, 2081-2091.	13.9	321

#	ARTICLE	IF	CITATIONS
55	Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2005, 149, 489-496.	1.2	317
56	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	1.8	311
57	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.6	299
58	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
59	Dabigatran Versus Warfarin. <i>Stroke</i> , 2013, 44, 1891-1896.	1.0	292
60	Evidence-Based Analysis of Amiodarone Efficacy and Safety. <i>Circulation</i> , 1999, 100, 2025-2034.	1.6	291
61	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002, 144, 282-289.	1.2	284
62	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002, 144, 282-289.	1.2	264
63	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	1.2	258
64	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
65	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	1.0	253
66	Amiodarone Interaction With β -Blockers. <i>Circulation</i> , 1999, 99, 2268-2275.	1.6	240
67	Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing. <i>Circulation</i> , 2006, 114, 11-17.	1.6	238
68	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 2325-2334.	6.3	236
69	Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. <i>Circulation</i> , 2009, 120, 1174-1180.	1.6	228
70	Irbesartan in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 928-938.	13.9	220
71	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	0.6	219
72	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	6.3	216

#	ARTICLE	IF	CITATIONS
73	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). <i>Lancet, The</i> , 2015, 385, 785-791.	6.3	214
74	Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. <i>American Heart Journal</i> , 2002, 143, 984-990.	1.2	211
75	Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. <i>American Journal of Cardiology</i> , 2003, 91, 9-14.	0.7	206
76	Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. <i>Journal of the American College of Cardiology</i> , 2001, 38, 167-172.	1.2	201
77	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	1.8	201
78	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	1.2	197
79	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
80	Subclinical Atrial Fibrillation in Older Patients. <i>Circulation</i> , 2017, 136, 1276-1283.	1.6	194
81	Canadian Trial of Physiological Pacing. <i>Circulation</i> , 2004, 109, 357-362.	1.6	184
82	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , 2008, 156, 37-43.	1.2	183
83	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	2.0	181
84	Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. <i>Stroke</i> , 2008, 39, 1482-1486.	1.0	177
85	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 753.	3.8	176
86	Asymptomatic or "Silent" Atrial Fibrillation. <i>Circulation</i> , 2003, 107, 1141-1145.	1.6	171
87	Atrial Pacing Periablation for Prevention of Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1999, 99, 2553-2558.	1.6	170
88	Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. <i>American Heart Journal</i> , 2006, 152, 967-973.	1.2	167
89	Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold. <i>Circulation</i> , 2006, 114, 104-109.	1.6	167
90	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfeTy and pharmacokinetics of oral dabiGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). <i>American Heart Journal</i> , 2012, 163, 931-937.e1.	1.2	164

#	ARTICLE	IF	CITATIONS
91	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	4.9	164
92	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	1.0	160
93	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	1.2	160
94	Dabigatran and Warfarin in Vitamin K Antagonist-“Naive and “Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
95	Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2012, 5, 566-570.	1.6	155
96	Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The β -Blocker Length Of Stay (BLOS) study. <i>American Heart Journal</i> , 2003, 145, 226-232.	1.2	152
97	Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. <i>European Heart Journal</i> , 2007, 28, 1746-1749.	1.0	152
98	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. <i>JAMA Neurology</i> , 2019, 76, 764.	4.5	147
99	Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010, 159, 348-353.e1.	1.2	146
100	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology</i> , The, 2018, 17, 1053-1060.	4.9	146
101	Canadian Implantable Defibrillator Study (CIDS): Study design and organization. <i>American Journal of Cardiology</i> , 1993, 72, F103-F108.	0.7	142
102	Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. <i>Heart Rhythm</i> , 2012, 9, 1241-1246.	0.3	141
103	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
104	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	1.6	133
105	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
106	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	1.0	131
107	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1796-1802.	1.2	129
108	Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. <i>Circulation</i> , 2010, 122, 2645-2652.	1.6	126

#	ARTICLE	IF	CITATIONS
109	Age of First Faint in Patients with Vasovagal Syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 49-54.	0.8	122
110	Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. <i>Heart Rhythm</i> , 2017, 14, 801-807.	0.3	122
111	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	2.0	119
112	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
113	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
114	Randomized Crossover Comparison of DDDR Versus VDD Pacing After Atrioventricular Junction Ablation for Prevention of Atrial Fibrillation. <i>Circulation</i> , 2000, 102, 736-741.	1.6	117
115	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). <i>American Heart Journal</i> , 2006, 152, 442-447.	1.2	117
116	Dual-Chamber Versus Ventricular Pacing. <i>Circulation</i> , 1996, 94, 578-583.	1.6	117
117	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016, 11, 526-533.	2.9	113
118	A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 138-144.	0.8	111
119	Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2001, 103, 1416-1421.	1.6	109
120	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	1.0	109
121	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	0.6	108
122	Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. <i>American Heart Journal</i> , 2004, 147, 837-840.	1.2	107
123	Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -. <i>Circulation Journal</i> , 2011, 75, 800-805.	0.7	107
124	Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. <i>Journal of the American College of Cardiology</i> , 2000, 36, 794-802.	1.2	106
125	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
126	Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes. <i>Circulation</i> , 2001, 103, 3081-3085.	1.6	102

#	ARTICLE	IF	CITATIONS
127	Screening for Atrial Fibrillation in the Older Population. <i>JAMA Cardiology</i> , 2021, 6, 558.	3.0	101
128	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	1.2	99
129	The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2004, 148, 649-654.	1.2	98
130	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 277-283.	0.9	96
131	Are Elderly Patients at Increased Risk of Complications Following Pacemaker Implantation? A Meta-Analysis of Randomized Trials. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 131-134.	0.5	96
132	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
133	Left Atrial Appendage Occlusion Study II (LAAOS II). <i>Canadian Journal of Cardiology</i> , 2013, 29, 1443-1447.	0.8	95
134	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	1.2	95
135	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	0.7	94
136	Patient outcomes using the European label for dabigatran. <i>Thrombosis and Haemostasis</i> , 2014, 112, 933-942.	1.8	94
137	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	1.2	94
138	Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. <i>American Journal of Cardiology</i> , 1983, 52, 1208-1213.	0.7	93
139	Postoperative Low-Molecular-Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	0.5	92
140	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	1.0	92
141	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	0.7	91
142	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	1.2	91
143	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
144	Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. <i>American Journal of Cardiology</i> , 2001, 88, 974-979.	0.7	83

#	ARTICLE	IF	CITATIONS
145	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	1.0	83
146	Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 224-228.	0.8	83
147	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	2.7	83
148	Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 1358-1362.	0.5	82
149	Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. <i>American Heart Journal</i> , 2003, 145, 430-437.	1.2	82
150	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	1.6	82
151	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1053-1061.	2.9	82
152	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
153	Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 890-923.	0.8	79
154	Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0129282.	1.1	79
155	Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: The need for randomized trials. <i>American Journal of Cardiology</i> , 1992, 69, 959-962.	0.7	78
156	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	1.2	78
157	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	1.0	78
158	Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011, 6, 90.	2.5	76
159	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
160	Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. <i>American Journal of Cardiology</i> , 1989, 63, 817-819.	0.7	75
161	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015, 196, 127-131.	0.8	74
162	Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. <i>American Heart Journal</i> , 2003, 145, 174-178.	1.2	72

#	ARTICLE	IF	CITATIONS
163	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	1.0	72
164	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	1.0	72
165	Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. <i>European Heart Journal</i> , 2005, 26, 1385-1393.	1.0	69
166	Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 246-252.e5.	2.4	67
167	The canadian registry of atrial fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. <i>American Journal of Cardiology</i> , 1998, 82, 82N-85N.	0.7	66
168	Interaction Between Digoxin and Dronedaron in the PALLAS Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1019-1025.	2.1	66
169	Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. <i>Circulation</i> , 2009, 120, 1927-1932.	1.6	63
170	Global Survey of the Frequency of Atrial Fibrillation Associated Stroke. <i>Stroke</i> , 2016, 47, 2197-2202.	1.0	62
171	Dronedaron in patients with congestive heart failure: insights from ATHENA. <i>European Heart Journal</i> , 2010, 31, 1717-1721.	1.0	61
172	Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. <i>BMJ Open</i> , 2018, 8, e017765.	0.8	60
173	Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. <i>Journal of the American College of Cardiology</i> , 1987, 10, 1145-1148.	1.2	59
174	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol. <i>American Heart Journal</i> , 2000, 140, 735-739.	1.2	59
175	Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2001, 104, 1622-1626.	1.6	59
176	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	1.0	59
177	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	1.2	59
178	Rhythm- and Rate-Controlling Effects of Dronedaron in Patients With Atrial Fibrillation (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	57
179	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	1.2	56
180	Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 381-387.	0.8	55

#	ARTICLE	IF	CITATIONS
181	Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. <i>Heart Rhythm</i> , 2012, 9, 1667-1673.	0.3	54
182	Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Canadian Journal of Cardiology</i> , 2013, 29, 652-658.	0.8	54
183	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1204-1209.	0.7	54
184	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. <i>JAMA Neurology</i> , 2020, 77, 43.	4.5	54
185	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020, 51, 1797-1804.	1.0	54
186	Meta-analysis of antiarrhythmic drug trials. <i>American Journal of Cardiology</i> , 1999, 84, 90-93.	0.7	53
187	Predictors of early and late stroke following cardiac surgery. <i>Cmaj</i> , 2014, 186, 905-911.	0.9	52
188	Rationale and Design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 19, 071121154351003-???	0.8	51
189	Additional Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1464-1465.	13.9	47
190	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	1.2	47
191	Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. <i>Current Opinion in Cardiology</i> , 2005, 20, 31-7.	0.8	47
192	Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. <i>International Journal of Stroke</i> , 2015, 10, 1031-1036.	2.9	46
193	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. <i>Stroke</i> , 2015, 46, 667-672.	1.0	46
194	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	0.7	46
195	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. <i>Circulation</i> , 2011, 124, 2649-2660.	1.6	45
196	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-CAF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
197	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <i>American Heart Journal</i> , 2020, 225, 69-77.	1.2	43
198	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	1.0	42

#	ARTICLE	IF	CITATIONS
199	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	1.2	42
200	Atrial fibrillation is associated with increased mortality: causation or association?. <i>European Heart Journal</i> , 2013, 34, 1027-1030.	1.0	40
201	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	1.2	39
202	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
203	Canadian Registry of ICD Implant Testing Procedures (CREDIT): Current Practice, Risks, and Costs of Intraoperative Defibrillation Testing. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 177-182.	0.8	38
204	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. <i>Open Heart</i> , 2016, 3, e000515.	0.9	38
205	Clinical Pharmacokinetics of N-acetylprocainamide. <i>Clinical Pharmacokinetics</i> , 1982, 7, 206-220.	1.6	37
206	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	0.8	37
207	Atrial fibrillation detected initially during acute medical illness: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 130-141.	0.4	37
208	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2020, 77, 1233.	4.5	37
209	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	1.6	37
210	Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. <i>American Heart Journal</i> , 2002, 143, 643-649.	1.2	36
211	Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). <i>Heart Rhythm</i> , 2010, 7, 1171-1177.	0.3	36
212	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
213	The management of patients with carotid sinus syndrome: is pacing the answer?. <i>Clinical Autonomic Research</i> , 2004, 14, i80-i86.	1.4	35
214	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	1.0	35
215	A Randomized Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1313-1316.	0.8	35
216	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 379, 986-987.	13.9	35

#	ARTICLE	IF	CITATIONS
217	Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2875-2886.	1.2	35
218	Combined Antiplatelet Therapy in Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S60-S63.	0.8	34
219	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	1.8	34
220	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	1.8	34
221	Role of oral anticoagulation in management of atrial fibrillation. <i>British Heart Journal</i> , 2004, 90, 813-817.	2.2	33
222	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. <i>Europace</i> , 2011, 13, 1118-1126.	0.7	33
223	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 389-395.	0.8	33
224	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle-aged individuals. <i>Cardiovascular Research</i> , 2021, 117, 1523-1531.	1.8	33
225	Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Rationale and protocol. <i>American Journal of Cardiology</i> , 1993, 72, F87-F94.	0.7	32
226	Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. <i>American Heart Journal</i> , 2003, 145, 418-423.	1.2	32
227	Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 215-218.	0.7	32
228	The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: A randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. <i>American Heart Journal</i> , 2012, 164, 146-152.	1.2	32
229	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	0.7	31
230	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	1.2	31
231	Relevance of Electrical Remodeling in Human Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 626-631.	2.1	30
232	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	1.2	30
233	Use and Misuse of Surrogate Outcomes in Arrhythmia Trials. <i>Circulation</i> , 2006, 113, 764-766.	1.6	29
234	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. <i>Europace</i> , 2014, 16, 174-181.	0.7	29

#	ARTICLE	IF	CITATIONS
235	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	0.8	29
236	Circadian variation of paroxysmal atrial fibrillation. <i>American Journal of Cardiology</i> , 2001, 87, 794-798.	0.7	28
237	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. <i>Heart Rhythm</i> , 2014, 11, 2156-2162.	0.3	28
238	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	1.0	28
239	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 324.	3.0	28
240	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
241	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2021, 78, 11.	4.5	28
242	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021, 143, 1863-1873.	1.6	28
243	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2273-2279.	0.7	27
244	Implantable cardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. <i>Heart Rhythm</i> , 2012, 9, 2068-2074.	0.3	26
245	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. <i>Europace</i> , 2017, 19, euw221.	0.7	26
246	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). <i>American Heart Journal</i> , 2018, 201, 160-163.	1.2	26
247	Atrial fibrillation occurring transiently with stress. <i>Current Opinion in Cardiology</i> , 2018, 33, 58-65.	0.8	26
248	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	5.1	25
249	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018, 34, 295-302.	0.8	25
250	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005795.	1.4	25
251	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 938-943.	1.0	25
252	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	1.0	25

#	ARTICLE	IF	CITATIONS
253	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	1.0	25
254	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	1.8	24
255	Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. <i>Heart Failure Reviews</i> , 2014, 19, 305-313.	1.7	24
256	Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. <i>American Heart Journal</i> , 2018, 199, 75-82.	1.2	24
257	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	2.5	23
258	Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. <i>American Heart Journal</i> , 2003, 146, 489-493.	1.2	22
259	Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016, 375, 2498-2500.	13.9	22
260	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	1.9	22
261	CLINICAL TRIALS OF PACING MODE SELECTION. <i>Cardiology Clinics</i> , 2000, 18, 1-23.	0.9	21
262	Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. <i>Journal of Hypertension</i> , 2007, 25, 307-313.	0.3	21
263	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	1.0	21
264	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017, 19, euw116.	0.7	20
265	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. <i>Blood</i> , 2008, 112, 33-33.	0.6	20
266	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
267	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	1.8	19
268	Concentration response relationships of amiodarone and desethylamiodarone. <i>American Heart Journal</i> , 1988, 115, 1208-1213.	1.2	18
269	Long-term amiodarone therapy and the risk of complications after cardiac surgery: Results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 633-637.	0.4	18
270	Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. <i>Heart Rhythm</i> , 2005, 2, 270-275.	0.3	18

#	ARTICLE	IF	CITATIONS
271	Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008, 155, 829-840.	1.2	18
272	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	1.8	18
273	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 113-120.	0.6	18
274	North American Vasovagal Pacemaker Study: Study Design and Organization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 844-848.	0.5	17
275	Worsening of Symptoms Before Presentation with Vasovagal Syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 954-959.	0.8	17
276	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010107.	1.6	17
277	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	0.7	17
278	Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 189-192.	0.9	16
279	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	0.7	16
280	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
281	Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. <i>Circulation</i> , 2020, 142, 1697-1699.	1.6	16
282	Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial. <i>Stroke</i> , 2014, 45, 2989-2994.	1.0	15
283	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
284	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	1.8	15
285	Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction - A combined analysis from multicenter trials. <i>Clinical Cardiology</i> , 2005, 28, 471-478.	0.7	14
286	Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 770-776.	0.8	14
287	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	0.7	14
288	Efficacy and Safety of Dabigatran Etxilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS ₂ Score. <i>Circulation Journal</i> , 2015, 79, 2138-2147.	0.7	14

#	ARTICLE	IF	CITATIONS
289	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	1.2	14
290	Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 2018, 121, 584-589.	0.7	14
291	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14
292	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
293	"An AVID Dissent": Commentary. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1712-1713.	0.5	13
294	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. <i>American Heart Journal</i> , 2000, 139, 752-760.	1.2	13
295	Anticoagulant-Related Bleeding and Mortality —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2522-2524.	1.2	13
296	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow-up cohort study. <i>Clinical Cardiology</i> , 2018, 41, 1273-1280.	0.7	13
297	Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. <i>European Heart Journal</i> , 2019, 40, 3026-3032.	1.0	13
298	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	0.7	13
299	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, . .	0.7	13
300	Diltiazem and Propranolol, Alone and in Combination, on Exercise Performance and Left Ventricular Function in Patients with Stable Effort Angina: A Double-Blind, Randomized, and Placebo-Controlled Study. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 57, 55-60.	0.0	12
301	Design and Use of a Quantitative Scale for Measuring Presyncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 888-893.	0.8	12
302	Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. <i>European Heart Journal</i> , 2011, 32, 2347-2349.	1.0	12
303	Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. <i>European Heart Journal</i> , 2014, 35, 1831-1833.	1.0	12
304	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e009364.	0.8	12
305	Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. <i>Heart Rhythm</i> , 2016, 13, 504-510.	0.3	12
306	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <i>Country Review Ukraine</i> , 2005, 7, C28-C33.	0.8	11

#	ARTICLE	IF	CITATIONS
307	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010, 125, e128-e131.	0.8	11
308	The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial. <i>Canadian Journal of Cardiology</i> , 2012, 28, 95-101.	0.8	11
309	Warfarin in Heart Failure. <i>New England Journal of Medicine</i> , 2012, 366, 1936-1938.	13.9	11
310	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation—the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018, 20, 253-262.	0.7	11
311	Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. <i>Heart Rhythm</i> , 2018, 15, 386-392.	0.3	11
312	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
313	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2846-2856.	1.6	11
314	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
315	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	1.4	11
316	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008548.	1.6	11
317	Potential demographic and baseline variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator — A prognostic indicator. <i>International Journal of Cardiology</i> , 2008, 126, 101-107.	0.8	10
318	Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. <i>Heart</i> , 2009, 95, 95-97.	1.2	10
319	Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 462-472.	0.8	10
320	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	1.0	10
321	Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12655.	0.4	10
322	Atrial fibrillation: guiding lessons from epidemiology. <i>Cardiology Clinics</i> , 2004, 22, 1-8.	0.9	9
323	Stroke prevention in patients with atrial fibrillation: The diagnosis and management of hypertension by specialists. <i>Canadian Journal of Cardiology</i> , 2006, 22, 485-488.	0.8	9
324	Age and Mental Health Predict Early Device-Specific Quality of Life in Patients Receiving Prophylactic Implantable Defibrillators. <i>Canadian Journal of Cardiology</i> , 2012, 28, 502-507.	0.8	9

#	ARTICLE	IF	CITATIONS
325	The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. <i>European Heart Journal</i> , 2015, 36, 1640-1642.	1.0	9
326	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	1.2	9
327	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. <i>Open Heart</i> , 2018, 5, e000800.	0.9	9
328	High-Sensitivity Estimate of the Incidence of New-Onset Atrial Fibrillation in Critically Ill Patients. , 2021, 3, e0311.		9
329	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. <i>CJC Open</i> , 2021, 3, 1482-1489.	0.7	9
330	The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: A substudy of the Canadian Trial of Physiological Pacing (CTOPP). <i>Heart Rhythm</i> , 2007, 4, 1024-1028.	0.3	8
331	Advances in treatment and management. <i>Nature Reviews Cardiology</i> , 2011, 8, 67-68.	6.1	8
332	An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. <i>Europace</i> , 2014, 16, 1117-1124.	0.7	8
333	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	1.8	8
334	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	1.8	8
335	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	1.4	8
336	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2022, 53, 45-52.	1.0	8
337	Implantable cardioverter defibrillators“for whom?. <i>Lancet, The</i> , 1998, 352, 338-340.	6.3	7
338	Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 388-394.	1.0	7
339	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 447-451.	0.9	7
340	Prevention of Vascular Events in Patients with Atrial Fibrillation:. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S52-S55.	0.8	7
341	Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. <i>Heart Rhythm</i> , 2012, 9, 217-224.e2.	0.3	7
342	Apical versus Non“Apical Lead: Is ICD Lead Position Important for Successful Defibrillation?. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 581-586.	0.8	7

#	ARTICLE	IF	CITATIONS
343	Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. <i>Europace</i> , 2019, 21, 445-450.	0.7	7
344	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. <i>Stroke</i> , 2020, 51, 2139-2147.	1.0	7
345	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	1.0	7
346	Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2014, 64, 585-587.	1.2	6
347	Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT. <i>International Journal of Stroke</i> , 2021, 16, 192-199.	2.9	6
348	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	1.2	6
349	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. <i>Canadian Journal of Cardiology</i> , 2021, 37, 803-809.	0.8	6
350	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
351	Permanent Pacemaker Therapy for Neurally Mediated Syncope. <i>Circulation</i> , 2012, 125, 2552-2553.	1.6	5
352	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2885-2886.	1.2	5
353	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , 2019, 21, 1023-1030.	0.7	5
354	Effectiveness of single- vs dual-coil implantable defibrillator leads: An observational analysis from the SIMPLE study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1078-1085.	0.8	5
355	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009591.	2.1	5
356	Appropriate Use of the Implantable Cardioverter Defibrillator: A Canadian Perspective. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1-4.	0.5	4
357	LVS-CHARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017735.	1.6	4
358	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab513.	0.4	4
359	The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: Role of amiodarone. <i>ACC Current Journal Review</i> , 1995, 4, 32-34.	0.1	3
360	A rare cause of implantable cardioverter-defibrillator failure: Short-circuiting via an unused pace/sense lead. <i>Heart Rhythm</i> , 2010, 7, 1630-1631.	0.3	3

#	ARTICLE	IF	CITATIONS
361	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	1.3	3
362	Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2633-2635.	1.2	3
363	Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. <i>Circulation</i> , 2019, 139, 757-759.	1.6	3
364	Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2020, 22, 144.	1.3	3
365	Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial". <i>Circulation</i> , 2012, 125, .	1.6	2
366	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial". <i>Circulation</i> , 2013, 127, e506.	1.6	2
367	Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial. <i>CJC Open</i> , 2020, 2, 354-359.	0.7	2
368	Prospective Long-term Follow-up of Silicone-polyurethane - insulated Implantable Cardioverter Defibrillator Leads. <i>Heart Rhythm</i> O2, 2021, 3, 57-64.	0.6	2
369	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1434-1441.	0.8	2
370	Benefits of left atrial appendage occlusion. <i>American Heart Journal</i> , 2006, 151, e3.	1.2	1
371	Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients. <i>Cardiac Electrophysiology Clinics</i> , 2011, 3, 651-661.	0.7	1
372	Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy". <i>Circulation</i> , 2013, 127, e278-9.	1.6	1
373	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial". <i>Circulation</i> , 2012, 125, e107-11.	1.6	1
374	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2682.	1.2	1
375	Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. <i>Heart Rhythm</i> , 2019, 16, 83-90.	0.3	1
376	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008655.	2.1	1
377	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	1.1	1
378	Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation. , 2008, , 185-195.		1

#	ARTICLE	IF	CITATIONS
379	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015, 6, 267-277.	0.5	1
380	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
381	Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998, 2, 52-53.	0.9	0
382	The Problem of Asymptomatic Ventricular Arrhythmias Among Survivors of Acute Myocardial Infarction: Role of Amiodarone. <i>ACC Current Journal Review</i> , 1998, 7, 12-14.	0.1	0
383	Trials of Physiologic Pacing. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 156-158.	0.9	0
384	Explaining the RE-LY Trial. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 334-6.	0.1	0
385	Dronedarone for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1353-1354.	1.2	0
386	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians". <i>Stroke</i> , 2012, 43, e46-7; author reply e49.	1.0	0
387	Reply to the Editor "Electrogram Confirmation of Atrial High-Rate Episodes. <i>Heart Rhythm</i> , 2012, 9, e17-e18.	0.3	0
388	Reply to the Editor "Shocks and Mortality versus Pacing and Mortality. <i>Heart Rhythm</i> , 2013, 10, e9-e10.	0.3	0
389	Prevention of Stroke in Patients With Atrial Fibrillation. , 2014, , 1129-1137.		0
390	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". <i>Circulation</i> , 2014, 130, e95.	1.6	0
391	Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014, 160, JC4.	2.0	0
392	Letter by Longtin et al Regarding Article, "Rates of and Factors Associated With Infection in 2009 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry". <i>Circulation</i> , 2015, 131, e517.	1.6	0
393	Response to Letter Regarding Article "Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events". <i>Circulation</i> , 2015, 131, e337-8.	1.6	0
394	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
395	Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation: an analysis from the SIMPLE study. <i>Europace</i> , 2018, 20, 1798-1803.	0.7	0
396	Clinical Trials of Pacing Modes. , 2007, , 337-356.		0

#	ARTICLE	IF	CITATIONS
397	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. Heart Rhythm O2, 2021, 3, 40-49.	0.6	0
398	Omega-3 fatty acids and sudden arrhythmic death. Herz, 2006, 31 Suppl 3, 59-64.	0.4	0